[go: up one dir, main page]

Zhang, 1999 - Google Patents

Design and synthesis of anticancer agents

Zhang, 1999

Document ID
8320663998656080662
Author
Zhang Y
Publication year

External Links

Snippet

Cancer claims the lives of more than six million people worldwide each year; enormous efforts have been devoted to develop effective agents to cure the disease. Three approaches have been taken in this study to develop effective anticancer agents:(1) the …
Continue reading at search.proquest.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Similar Documents

Publication Publication Date Title
Mondal et al. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview
Steinmetzer et al. Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase
Fingleton Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects
Nuti et al. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors
Amin et al. Design of aminopeptidase N inhibitors as anti-cancer agents
Skiles et al. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors
Egeblad et al. New functions for the matrix metalloproteinases in cancer progression
Zhong et al. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer
Acharya et al. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases
Pepper Role of the matrix metalloproteinase and plasminogen activator–plasmin systems in angiogenesis
Koivunen et al. Tumor targeting with a selective gelatinase inhibitor
Mai et al. Targeting legumain as a novel therapeutic strategy in cancers
Cottam et al. Regulation of matrix metalloproteinases-their role in tumor invasion and metastasis
DANØ et al. Cancer invasion and tissue remodeling‐cooperation of protease systems and cell types
Mohan et al. Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine
Hua et al. Matrix metalloproteinases in tumorigenesis: an evolving paradigm
Brown Matrix metalloproteinase inhibitors in the treatment of cancer
Rudek et al. Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
Michaelides et al. Recent advances in matrix metalloproteinase inhibitors research
US20110300147A9 (en) Inhibiting tumor cell invasion, metastasis and angiogenesis
Cerofolini et al. Mechanism and inhibition of matrix metalloproteinases
JP4603162B2 (en) New urokinase inhibitor
US20110002992A1 (en) N-sulphonylated amino acid derivatives, method for the production and use thereof
Barthel et al. Synthesis and biological characterization of protease-activated prodrugs of doxazolidine
CA2778503A1 (en) Macrocyclic inhibitors of serine protease enzymes